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Abstract
Background: Many studies of cocaine-responsive gene expression have focused on changes occurring during
cocaine exposure, but few studies have examined the persistence of these changes with cocaine abstinence.
Persistent changes in gene expression, as well as alterations induced during abstinence may underlie long-lasting
drug craving and relapse liability.
Results: Whole-genome expression analysis was conducted on a rat cocaine binge-abstinence model that has
previously been demonstrated to engender increased drug seeking and taking with abstinence. Gene expression
changes in two mesolimbic terminal fields (mPFC and NAc) were identified in a comparison of cocaine-naïve rats
with rats after 10 days of cocaine self-administration followed by 1, 10, or 100 days of enforced abstinence (n = 6-
11 per group). A total of 1,461 genes in the mPFC and 414 genes in the NAc were altered between at least two
time points (ANOVA, p < 0.05; ± 1.4 fold-change). These genes can be subdivided into: 1) changes with cocaine
self-administration that do not persist into periods of abstinence, 2) changes with cocaine self-administration that
persist with abstinence, 3) and those not changed with cocaine self-administration, but changed during enforced
abstinence. qPCR analysis was conducted to confirm gene expression changes observed in the microarray analysis.
Conclusions: Together, these changes help to illuminate processes and networks involved in abstinence-induced
behaviors, including synaptic plasticity, MAPK signaling, and TNF signaling.
Background
A hallmark of cocaine addiction is continued drug crav-
ing and relapse propensity despite long-term drug absti-
nence. Development of effective cocaine addiction
treatments therefore requires therapies that decrease the
likelihood of relapse to cocaine abuse in the recovering
addict. A central theme of cocaine abuse research is the
role of neurobiological changes (e.g., electrophysiology,
neurochemistry, neuroanatomy, epigenetic, transcrip-
tomic, proteomic) in the development and maintenance
of the addicted behavioral phenotype (i.e., increased
drug-seeking and drug-taking).
Cocaine addiction generally starts with recreational
use and deteriorates over time into a compulsive and
chronically relapsing drug-taking disorder [1]. Stress,
environmental cues, and conditioned stimuli have been
demonstrated clinically to play a role in cocaine relapse
[2-4]. While initiating drug abstinence can be accom-
plished through in-patient treatment, maintaining
cocaine abstinence has proven difficult [5]. In controlled
clinical trials, prolonged cocaine abstinence is often
achieved by only a minority of patients [6-8]. This may
be due to increases in cocaine craving during drug absti-
nence [9]. Understanding the persistent neurobiological
changes that contribute to continued drug craving dur-
ing abstinence and relapse potential represents an
important step towards identifying treatments that
reduce the likelihood of relapse [10].
There is a growing understanding of the acute gene/
protein expression changes with cocaine administration
(either non-contingently or self-administered) that may
be important to the development and expression of
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ber of studies have examined whether these changes
revert to normal levels or remain altered with cocaine
abstinence. Observations of molecular changes persisting
into or occurring during this abstinence period provide
the opportunity to identify genes and their protein
counterparts that could be used as therapeutic targets to
decrease relapse liability.
The development of animal models of cocaine abuse
and abstinence has led to the identification of rodent
behaviors similar to those of human cocaine abusers.
Most notably, time-dependent increases in cocaine seek-
ing and taking behaviors haveb e e no b s e r v e di nt h er a t
model of cocaine abuse and enforced abstinence
employed in this study [12-14]. Similar observations
have been made using other animal models of prolonged
abstinence from cocaine [15,16]. Molecular analyses of
these models have not only identified changes in gene
or protein expression [12,17-19], but have also corre-
lated gene expression with cocaine-responsive behaviors
[20,21]. Many of the existing reports used targeted
approaches to quantify specific gene and protein expres-
sion changes during abstinence from cocaine. Large-
scale discovery studies with long-term enforced absti-
nence following cocaine self-administration are limited
and transcriptomic studies, in particular, have not been
conducted.
The self-administration paradigm used in this study
exhibits increased reinforcing efficacy, drug seeking, and
drug taking with at least 7 days, and as long as 100
days, of abstinence after a period of cocaine self-admin-
istration [12-14,22]. Examination of mesolimbic struc-
tures in these animals is warranted by the roles that
these structures, including the medial prefrontal cortex
(mPFC) and nucleus accumbens (NAc), play in reward
and behavioral responses to stimuli. Both of these brain
regions have been implicated in cocaine abuse and
withdrawal through imaging [23-25], behavioral
[20,21,26], and molecular [12,17-19] studies. We have
conducted targeted mRNA and epigenetic analysis from
this model previously [12]. The aim of the present
study was to extend this initial analysis of mesolimbic
dopaminergic terminal regions by providing a genome-
wide characterization in both the mPFC and the NAc of
rats following 10 days of cocaine self-administration and
after increasing periods of enforced abstinence from
cocaine (1, 10, and 100 days). Identification of genes
persistently altered in expression by cocaine or altered
during a period of cocaine abstinence provides insight
into the mechanisms involved in the long-term beha-
vioral changes that occur with cocaine abuse and illumi-
nates novel potential new targets for pharmacological
intervention.
Results
Animals
Behavioral analyses of the rat cocaine self-administration
paradigm and time points used in this study have been
published previously [12,14,27]. The specific animals
used in this study represent an independent set that was
not behaviorally tested (e.g. progressive ratio or extinc-
tion responding) to avoid any confounding effects of
behavioral testing on gene expression. All cocaine self-
administering groups were maintained on a continuous
access (24 hours/day) discrete trials (DT) schedule for
10 days. Trials were limited to 4 trials per hour (DT4).
After 10 days of DT4 responding, animals were sub-
jected to 1, 10, or 100 days of enforced abstinence. The
cocaine intake data for the specific animals used in this
study is presented in Table 1. No significant differences
were observed in the total cocaine intake of each group
or the average number of daily injections. The similarity
in total cocaine intake and responding between groups
minimizes the possibility that exposure to differing
Table 1 Cocaine intake data for samples
Arrays qPCR Confirmation
Group N Average
Total Intake
Average Injections
Per Session
N Average
Total Intake
Average Injections
Per Session
mPFC Naïve 6 -* - 11 - -
1-day Abstinence 6 934 ± 108 mg/kg 62 ± 7 6 934 ± 108 mg/kg 62 ± 7
10-days Abstinence 7 950 ± 105 mg/kg 63 ± 7
100-days Abstinence 6 856 ± 42 mg/kg 57 ± 3 8 855 ± 39 mg/kg 57 ± 3
NAc Naïve 5 -* - 11 - -
1-day Abstinence 5 932 ± 118 mg/kg 57 ± 28 6 934 ± 108 mg/kg 62 ± 7
10-days Abstinence 5 951 ± 116 mg/kg 63 ± 8 7 950 ± 105 mg/kg 63 ± 7
100-days Abstinence 8 855 ± 39 mg/kg 57 ± 3
* Naïve animals were not exposed to cocaine, and therefore have zero intake. There were no significant differences in cocaine intake or number of injections per
session between groups. “Arrays” indicates animals used for microarray analysis and “qPCR Confirmation indicates animals used for confirmatory qPCR analysis.
All of the samples from the array analysis were included in the qPCR confirmation. Data is presented as Mean ± S.D.
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Page 2 of 13amounts of cocaine, or a difference in self-administra-
tion behavior, could account for gene expression
changes observed. Microarray studies of the mPFC were
conducted on naïve, 1-day abstinent, and 100-days absti-
nent animals (n = 6/group). Microarray studies of the
NAc were conducted on naïve, 1-day abstinent, and 10-
d a y sa b s t i n e n ta n i m a l s( n=5 / g r o u p )f r o mt h es a m e
cohort. For confirmatory qPCR analyses of gene expres-
sion levels, a larger number of samples were tested,
including those included in microarray studies. Addi-
tionally, while microarrays were conducted on samples
f r o mt h r e et i m ep o i n t s ,a l lf o u rt i m ep o i n t sw e r eu s e d
for these confirmation studies (naïve, n = 11; 1-day, n =
6; 10-days, n = 7; and 100-days, n = 8) to provide finer
temporal resolution.
Microarray analysis
In the mPFC, gene products corresponding to a total of
21,814 probes (of the 44,000 total probes on the arrays)
were confidently detected, based on signal intensity at a
fixed value above background levels. In the NAc analysis,
mRNAs for a total of 19,015 probes were detected. Dif-
ferentially expressed genes were identified through a
combination of statistical significance (p < 0.05, One-way
ANOVA between groups) and a fold change filter of =1.4
fold change (Figure 1A&1B). This illuminated 1,461 gene
expression changes in the mPFC (representing 6.7% of
the total mRNA species detected) and 414 gene expres-
sion changes in the NAc (2.2% of the total detected).
These changes demonstrated three types of temporal
profiles (Figure 1C). Category 1 changes are those that
occurred with cocaine self-administration (either up- or
down-regulated at 1-day of abstinence), but that did not
persist into longer periods of abstinence (10- or 100-
days). A majority of the mPFC gene expression changes
belonged to this category (793 of 1,461); however, only a
s m a l lf r a c t i o no fc h a n g e si nt h eN A c( 6 8o f4 1 4 )e x h i b -
ited this expression pattern. Category 2 changes are those
Figure 1 Analysis of expression changes from the microarray studies. Venn diagrams illustrate the changes identified by microarray analysis
of naïve animals, and animals following 1 and 10 or 100 days of abstinence. (A) In the mPFC, 21,814 probes were detected as present. Of these,
1,461 were changed by greater than 1.4 fold with p < 0.05 (ANOVA) and can be split into three categories based on expression profile: changed
between naïve and 1-day (793), naïve and 100-days (480) or both (188). (B) In the NAc, 19,015 probes were detected as present. Of these, 414 were
changed by greater than 1.4 fold with p < 0.05 (ANOVA), and can be split into the same three categories: changed between naïve and 1-day (68),
naïve and 10-days (314) or both (32). (C) The three categories of gene expression changes can be segregated into (1) changes that occur with
cocaine self-administration (SA) that do not persist, (2) changes that occur with cocaine SA that do persist, and (3) changes that occur during
abstinence. Small graphs indicate the expression profile of changes in each category, where the x-axis represents group (naïve, 1-day and 10- or
100-days abstinent) and the y-axis represents percent (%) of naïve expression. (D) When comparing the gene expression changed between the
mPFC and NAc, a majority (97%) are unique to one brain region or the other. Only a small fraction (50) is changed in both brain regions.
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sisted into periods of abstinence (changed at 1-day and
remained changed with enduring abstinence). A small
number of gene expression changes from each brain
region (188 mPFC; 32 NAc) belonged to this category.
Finally, category 3 changes are those that did not occur
with cocaine self-administration, but changed during the
period of abstinence (not changed at 1-day, but changed
at 10- and/or 100-days). Approximately 33% of the
changes in the mPFC (480 of 1,461) and 76% of the
changes in the NAc (314 of 414) belong to this category.
A comparison of the genes changed at any time point
between the mPFC and NAc reveals that a limited num-
ber of changes were observed in both brain regions (Fig-
ure 1D). Of the total of 1875 gene expression changes,
less than 3% were detected in both the mPFC and the
NAc. A full list of gene expression changes is presented
in Additional File 1: Table S1, and has been uploaded to
the Gene Expression Omnibus online database.
Confirmatory qPCR
qPCR analysis was used to confirm a subset of gene
expression changes observed in the microarray analyses.
Genes chosen for qPCR confirmation were selected
based on ontological classes with potential roles in
drug-induced changes in the brain. Additional genes
were included in the confirmation studies based on pre-
vious reports of cocaine-responsive gene expression (see
Additional File 2: Table S2, for a full list and gene
expression assay information).
Differentially regulated genes confirmed in this study
(13 total; 4 mPFC, 9 NAc), belong to each of the 3 cate-
gories described above (Figure 2). In the mPFC, neurofi-
lament light (Nefl) was the only category 1 change,
with a 20% decrease in the mPFC at 1-day of abstinence
(Figure 2A). Category 2 changes included a 23%
decrease in levels of CD47 at 1-day that persisted
through 10-days of abstinence (21%), and an increase in
levels of dopamine receptor D5 (Drd5) at 1-day (40%)
Figure 2 Confirmed changes in mPFC gene expression. Four changes in gene expression were confirmed in the mPFC with qPCR analysis. (A)
Neurofilament light is decreased by 20% at 1-day of abstinence (p < 0.05). (B) CD47 expression is decreased from naïve at 1-day (23%, p < 0.05)
and 10-days of abstinence (21%; p < 0.01). (C) Dopamine receptor D5 (Drd5) expression is increased from naïve at 1-day (40%; p < 0.01) and
100-days (41%; p < 0.01). (D) Adenosine A2B receptor (Adora2b) expression is decreased from naïve at 10-days of abstinence (20%; p < 0.05).
Statistical analysis was performed by one-way ANOVA with Student-Newman-Keuls post hoc testing; * p < 0.05, ** p < 0.01.
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Page 4 of 13and 100-days of abstinence (41%) (Figure 2B&2C).
Finally, levels of adenosine A2B receptor (Adora2b)
were unchanged by cocaine administration, but were
reduced by 20% after 10-days of abstinence (Category 3
change) (Figure 2D).
In the NAc, nine genes were confirmed, most of
which displayed a category 3 profile of changing during
abstinence. These include beta-catenin (32% increase at
10-days), adenylate cyclase-associated protein 2 (Cap2;
206% increase at 10-days), cysteine-rich protein 2
(Crip2; 17% increase at 10-days), dynamin 2 (Dnm2;
167% increase at 10-days), early growth response 2
(Egr2; 55% decrease at 100-days), fucosyltransferase 8
(Fut8; 25% increase at 10-days), glial fibrillary acidic
protein (GFAP; 87% increase at 10-days), and G-protein
coupled receptor 88 (Gpr88; 277% increase at 10-days)
(Figure 3A). The 5-hydroxytryptamine receptor 1d
(Htr1d), which was decreased at 1-day (28%) and
remained decreased at 10-days (20%) represents the only
confirmed category 2 change (Figure 3B).
C o n s i s t e n tw i t ho u rp r e v i o u sf i n d i n g si nt h i sa n i m a l
model and at the same time points [12], the microarray
analysis performed in this study detected significant
changes in activity-related cytoskeletal associated protein
(Arc), cocaine and amphetamine-related transcript
(CART), early growth response 1 (Egr1), FBJ osteosar-
coma oncogene (Fos), neuropeptide Y (NPY), and
nuclear receptor subfamily 4a1 (Nr4a1) transcript levels.
Prior to the microarray analysis, we had examined these
genes by qPCR based on their known responsiveness to
cocaine and have already reported these results [12].
Persistent decreases (Category 2 or 3) in Arc, Fos, and
Nr4a1 were observed in both the mPFC and NAc. Cate-
gory 1 changes in CART, NPY (both increased at 1-day)
and Egr1 (decreased at 1-day) in the mPFC were also
confirmed by qPCR (Table 2).
Ontological and Network analysis
Analysis of the Gene Ontology (GO) categories of
changes in each brain region identified a number of
molecular functions significantly regulated with
cocaine self-administration and abstinence. The mole-
cular functions altered were anatomically distinct. In
the mPFC, the most-represented class, consisting of
~ 25% of the changes identified by microarray analysis,
was protein serine/threonine kinase activity, followed
closely by structural components of the ribosome and
monovalent inorganic cation transporter activity
(~ 15% of the total changes each). The most repre-
sented classes among the changes in NAc gene expres-
sion were hydrolase activity (~ 40%), and phosphoric
ester hydrolase activity (~ 10%).
Network analysis, conducted using Ingenuity Pathways
Analysis software (Ingenuity Systems, Redwood City,
CA), was performed to determine the relationships
between confirmed gene expression changes from this
study and previously reported changes from this model
[12]. To complement the GO analysis, additional analy-
sis was conducted to determine whether these genes are
implicated in specific pathways and/or biological func-
tions and diseases. Only those genes confirmed by qPCR
were used in this analysis. In the mPFC, these molecules
comprise a network of interactions involved in synaptic
plasticity, calcium signaling, and mitogen activated pro-
tein kinase/extracellular signal-regulated kinase (MAPK/
ERK) signaling. In the NAc, all 12 molecules were com-
ponents of a network of interactions with members
linked to the neuronal cytoskeleton, glial cells, and Wnt
and tumor necrosis factor (TNF) signaling functions.
Discussion
This study represents the first microarray analysis of
mesolimbic gene expression following long-term
enforced abstinence from cocaine self-administration.
Transcriptomic studies of cocaine-induced gene expres-
sion changes have been conducted, but these have
focused on non-contingent cocaine administration and
no or limited (~ 1 day) abstinence. The work conducted
in the present study used a model with well-character-
ized behavioral changes during periods of abstinence,
and used animals not subjected to behavioral testing
during abstinence (e.g. progressive ratio or extinction
responding) so that the gene expression changes
observed are free from the effects elicited by behavioral
testing conducted before sacrifice. Additionally, it is
important to note that all groups (1, 10, and 100 days of
abstinence) self-administered equivalent amounts of
cocaine over the 10 days of discrete trial cocaine self-
administration. This time-course analysis of gene
expression allows for discrimination of gene expression
changes associated with increased drug seeking (10 and
100 days of abstinence) from those that occur with
cocaine self-administration, but do not persist for as
long as increased drug seeking and taking (1 day of
abstinence).
The literature describes a number of neurobiological
changes (e.g. altered gene/protein expression, neuro-
transmitter levels, epigenetic events) with different mod-
els of cocaine abuse, (for a review see [11,28]). Whether
these changes persist into periods of abstinence, how-
ever, has generally not been determined. In this study,
gene expression changes that occurred as a result of
cocaine self-administration and abstinence segregated
into three categories of expression patterns. Category 1
changes were defined as those that occur with cocaine
use, but do not persist into periods of abstinence. These
were observed as changes only between naïve animals
and 1-day abstinent animals. After only 1 day of
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Page 5 of 13Figure 3 Confirmed changes in NAc gene expression. Nine changes in gene expression were confirmed in the NAc with qPCR analysis in
this study. (A) Eight of the changes have the profile of changing in expression during abstinence (either at 10 or 100-days of abstinence). These
genes are beta-catenin (increased by 32% at 10-days; p < 0.001), adenylate cyclase-associated protein 2 (Cap2; increased by 206% at 10-days; p <
0.001), cysteine-rich protein 2 (Crip2; increased 17% at 10-days; p < 0.05), dynamin 2 (Dnm2; increased 167% at 10-days; p < 0.001), early growth
response 2 (Egr2; decreased by 55% at 100-days; p < 0.05), fucosyltransferase 8 (Fut8; increased 25% at 10-days; p < 0.01), glial fibrillary acidic
protein (GFAP; increased 87% at 10-days; p < 0.05), and G-protein coupled receptor 88 (Gpr88; increased 277% at 10-days; p < 0.01). (B)
5-hydroxytryptamine receptor 1d (Htrd1) is decreased by 28% at 1-day (p < 0.001) and by 20% at 10-days of abstinence (p < 0.01). Statistical
analysis was performed by one-way ANOVA with Student-Newman-Keuls post hoc testing; * p < 0.05, ** p < 0.01, #p < 0.001.
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Page 6 of 13abstinence, an increase in drug seeking and drug taking
is not observed [12], so the changes in gene expression
observed at this point may be necessary, but are not suf-
ficient, to cause the incubated phenotype and are pri-
marily due to exposure to cocaine. Category 2 changes
are those that occur with cocaine use that persist with
periods of abstinence. These were observed to be altered
in the comparisons between naïve and 1-day abstinent
animals and between naïve and 10- or 100-day abstinent
animals. These alterations may result from cocaine
exposure, but do not return to naïve levels with cessa-
tion of the cocaine stimulus. The persistence of these
changes may indicate their potential role in the develop-
ment (10 days) or maintenance (100 days) of absti-
nence-persistent increases in drug seeking and drug
taking behaviors. Category 3 changes consist of genes
that were unchanged with cocaine use, but are altered
during the abstinence period. While not immediately
affected by cocaine exposure, this set of changes may
result from initiation or continuation of abstinence.
These may function synergistically with other (category
2) changes to contribute to the development of
increased drug-seeking and -taking.
mPFC
The mPFC mediates executive function and decision
making processes and is therefore a key neuroanatomi-
cal region in addictive behaviors [29,30]. In response to
cocaine administration, changes in metabolic activity,
neurotransmitter systems, and gene or protein expres-
sion occur in the mPFC (for a review see [28]). In this
study, a large number of gene expression changes were
observed in the mPFC both as a result of cocaine self-
administration and with subsequent enforced abstinence.
Most of these changes occurred as a direct result of the
cocaine self-administration (981) and a majority (793)
returned to cocaine-naïve levels with cessation of
cocaine self-administration. As expected many changes
(category 1) in gene expression require continued
cocaine stimulus to remain altered, and return to nor-
mal levels after the stimulus is removed. A subset of
genes (188) remained changed after 100-days of
enforced abstinence. Persistence of gene expression
changes with abstinence (category 2) requires mainte-
nance via other mechanisms. Epigenetic changes occur
in response to cocaine, and may constitute a regulatory
mechanism for persistent changes in gene expression
[12,31]. Changes (480) that do not occur during cocaine
self-administration, but are induced with abstinence
(category 3) may reflect the withdrawal of the cocaine
stimulus and development of the incubated phenotype.
Altered gene expression of Adora2b, Arc, CART,
Cd47, Drd5, Egr1, Fos, Nefl, NPY, and Nr4a1 were con-
firmed by qPCR. We have previously described altered
expression of Arc, CART, Egr1, Fos, NPY, and Nr4a1 in
these samples in a directed study of genes with known
relevance to drug abuse [12]. A number of the qPCR
confirmation analyses that did not reach statistical sig-
nificance demonstrated expression profiles similar to
those observed in the microarray. This may reflect the
effects of neuroanatomical complexity on quantitation
of gene expression endpoints and the inclusion of larger
numbers of animals in the confirmatory experiments.
This work identified altered expression of two G-pro-
tein coupled receptors (GPCRs; Adora2b, Drd5), a cell-
surface signaling molecule (CD47), and a component of
the neuronal cytoskeleton (Nefl). Increased Drd5, and
signaling through this receptor, have been reported to
decrease responsiveness to cocaine [32,33]. Similarly,
adenosine signaling has been implicated in drug addic-
tion. Specifically, activation of Adora2b receptors
attenuates cocaine-conditioned place preference [34].
Although the mechanisms underlying these effects are
unclear, Drd5 signaling is implicated in neuronal
Table 2 Gene expression changes reported previously
Expression Level (% of Naïve Control)
Gene Name Gene ID Nv1 Nv10 Nv100
mPFC Activity-related cytoskeleton-associated protein Arc 43.9 ± 14** 76.8 ± 12 51.8 ± 10**
Cocaine and amphetamine regulated transcript CART 725.2 ± 130** 191.9 ± 55 190.3 ± 86
Early growth response 1 Erg1 59.6 ± 9.2* 74.7 ± 15 74.5 ± 5.3
FBJ osteosarcoma oncogene Fos 41.7 ± 12** 58.1 ± 11** 53.1 ± 6.8**
Neuropeptide Y Npy 158.4 ± 21
# 94.5 ± 9.5 91 ± 5.2
Nuclear receptor subfamily 4, group A, member 1 Nr4a1 35.1 ± 11** 53.4 ± 12* 49.4 ± 7.7*
NAc Activity-related cytoskeleton-associated protein Arc 83.5 ± 22 73.7 ± 12 49.5 ± 6.4*
FBJ osteosarcoma oncogene Fos 53.9 ± 16** 60.3 ± 6.7** 51.7 ± 62**
Nuclear receptor subfamily 4, group A, member 1 Nr4a1 65.7 ± 20 63.4 ± 11 48.1 ± 5.1*
Data is presented as mean ± standard error of the mean (SEM), ANOVA with Student-Newman-Keuls post hoc testing; * p < 0.05, ** p < 0.01, # p < 0.001. Data
previously reported in [12].
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Page 7 of 13activities including long-term potentiation (LTP; [35]),
and reinforcement learning [36], while both Drd5 [37]
and Adora2b [38] appear to affect Ca
2+ dynamics.
The decrease in CD47 expression in this model is a
novel observation and is of interest due to its function
in neuronal development [39,40]. Nefl functions in
cytoskeletal organization and cell-surface receptor remo-
deling [41,42], which may be impaired with the observed
decrease in expression at 1-day of abstinence. Pre-
viously, changes in protein levels and post-translational
modifications of Nefl, and other neurofilament isoforms,
have been reported with cocaine, morphine, alcohol, and
nicotine administration [43-45].
We have previously reported a directed analysis of
immediate early genes (IEGs; Arc, Egr1, Fos, and Nr4a1)
and neuropeptides (NPY and CART) in this animal
model [12]. These genes were also identified in the cur-
rent discovery microarray analysis, providing increased
confidence in the microarray findings. These genes play
important roles in a number of neuronal processes
including learning and memory [46,47], synaptic plasti-
city [48-50], Ca
2+ signaling [51,52], and MAPK signaling
[51].
Network analysis was conducted using the set of con-
firmed mPFC gene expression changes, and revealed
that Cart, NPY, Nr4a1, Fos, Egr1, Adora2b and Drd5 all
interact (directly or indirectly) with the MAPK/ERK
pathway. While altered expression of MAPK/ERK path-
way elements was not detected in this study, changes in
expression and activity levels of MAPK/ERK genes have
been reported (for a review see [28]) and this pathway is
thought to play an important role in drug-induced
changes in the brain [53,54]. Regulators of Ca
2+
dynamics were also identified in the network analysis.
T h ec h a n g e si nD r d 5 ,A d o r a 2 b ,C D 4 7a n dC A R T
expression may indicate a decrease in intracellular Ca
2+
signaling that occurs with cocaine self-administration
and persists into periods of abstinence [40,52,55,56].
Additionally, the gene expression changes identified
indicate that synaptic plasticity may be affected by
cocaine self-administration and abstinence. Persistent
reductions in levels of CD47 and Arc, and inductions in
levels of Drd5 and NPY suggest altered synaptic plasti-
city process involved in memory formation and removal
of old memory traces, respectively [50,57,58]. A poten-
tial reduction in synaptic plasticity in the mPFC with
cocaine self-administration/abstinence is hypothesized
based on levels of CD47, Nefl, Arc, Egr1, and NPY
[39,42,48-50]. These data are in agreement with studies
of the direct role of psychostimulants on mechanisms of
synaptic plasticity, including LTP and LTD, in the meso-
limbic system [59,60]. In total, these gene expression
changes may contribute to persistently altered synaptic
plasticity in the mPFC.
NAc
The central role of the NAc in psychostimulant reward is
well documented [61]. While cocaine exerts common
actions on the NAc and mPFC [62], we observed little
overlap (50 of the 1875 total gene expression changes
(mPFC + NAc)) between these brain regions. The regu-
lated genes common to both brain regions include IEGs
reported previously [12], various signaling molecules, and
genes involved in cellular metabolism. When the micro-
array datasets were examined by ontological analysis dis-
tinct molecular functions were observed in each brain
region. This indicates that the functional changes occur-
ring in the mPFC and NAc may differ and may ultimately
play different roles in abstinence-dependent behaviors.
Unlike the mPFC, fewer category 1 and 2 changes
were observed in the NAc (100 of 414 total), than cate-
gory 3 changes (those changed specifically during absti-
nence) (314). Of the cocaine-induced changes, only 32
persisted into periods of abstinence (category 2), while
the remainder returned to pre-cocaine levels. Arc, Beta-
catenin, Cap2, Crip2, Dnm2, Egr2, Fos, Fut8, GFAP,
Gpr88, Htr1d, and Nr4a1 were all confirmed by qPCR
to be differentially expressed. We have previously
demonstrated the responsiveness of Arc, Fos and Nr4a1
in this animal model [12].
Published data regarding Cap2, Crip2, Fut8, and
Gpr88 in the brain are limited, with no previous reports
of cocaine-responsiveness. Crip2 (a LIM-domain pro-
tein), Cap2 (an adenylate cyclase-associated protein) and
Dnm2 are cytoskeletal function and organization genes
[63,64]. Interestingly, Dnm2 is regulated by the tran-
scription factor Arc, also altered in the NAc with
cocaine [12,65]. Among the remaining changes, Egr2
and GFAP have been previously demonstrated to be
cocaine-responsive [66-68]. Htr1d has been linked with
a number of psychiatric disorders [69,70]. Changes in
the expression of these genes may also indicate cocaine
induced alterations in receptor signaling, glial cell func-
tion, and synaptic plasticity.
Beta-catenin, which was increased at 10-days of absti-
nence in this study, is a well-characterized protein that
regulates cell growth as a part of the Wnt signaling
pathway. As a part of Wnt signaling, beta-catenin also
plays a role in synaptic plasticity [71,72]. In response to
chronic cocaine, beta-catenin has been shown to
increase in a number of brain regions [73-75]. Fut8, a
fucosyltransferase protein, also increased at 10-days of
abstinence in this study, has been shown to increase
upon Wnt/beta-catenin activation [76], indicating that
there may be a coordinated activation of Wnt signaling
during periods of abstinence from cocaine.
Network analysis of the confirmed genes in the NAc
identified a TNF-centered network. Generally involved
in inflammatory processes, TNF has not been
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cocaine. Studies performed on the effects of cocaine on
macrophages have reported that cocaine suppresses
LPS-stimulated TNF expression [77,78]. TNF induction
was recently demonstrated to reduce conditioned place
preference and locomotor sensitization caused by
methamphetamine and morphine administration [79]. If
TNF does play a role in the behavioral responses to
cocaine, these additional genes may represent regulatory
and effector elements of a TNF network.
While these reported changes represent new insights
into abstinence-induced changes in the brain, localization
of these changes to specific cell types is still to be deter-
mined. As with other functional genomic and proteomic
approaches looking at dissected brain regions, even these
specific dissections contain a heterogeneous cellular
population. Future molecular neurobiology studies that
seek to extend these, and other findings, will need to uti-
lize techniques (e.g. laser capture microdissection and
fluorescent in-situ hybridization) to localize changes to
specific cell types and neuronal networks [80].
Conclusions
In addition to offering further evidence of long-lasting
changes in gene expression following abstinence from
cocaine self-administration, these results identify cellular
processes that may regulate the development and/or
maintenance of incubation of drug-seeking and drug-tak-
ing. A number of additional changes in gene expression
remain to be examined in future studies, but the results
presented here support the finding that persistent shifts
in gene expression can last long into abstinence. In the
mesolimbic reward pathway, changes in the mPFC may
be more pronounced than in the NAc and involve mostly
distinct sets of genes. This may indicate different meta-
plastic processes occur in these brain regions with the
development and expression of abstinence-induced beha-
viors. In the mPFC, changes in MAPK/ERK and calcium
signaling and in synaptic plasticity occur. The alterations
i nt h eN A cs u g g e s tap o s s i b l er o l eo fW n ta n dT N F -
mediated signaling in cocaine-associated behaviors.
Together the findings of this study highlight a number of
pathways and processes in the brain that may play roles
in the development and maintenance of abstinence-
induced drug seeking and drug taking. A clear under-
standing of how these novel changes contribute to
relapse liability will not onlyi n c r e a s eo u rk n o w l e d g eo f
the neurobiology of addiction, but will provide targets for
therapeutic development.
Methods
Cocaine self-administration
The surgical and cocaine self-administration procedures
used have been described previously [12,18]. Briefly,
male Sprague-Dawley rats (Harlan Inc., IN) were
implanted with a chronic indwelling Silastic cannula in
the right jugular vein, and trained to self-administer
cocaine hydrochloride through exposure to a fixed ratio
1 (FR1) schedule of reinforcement as described pre-
viously [12,14]. After establishing a stable daily intake of
cocaine (40 infusions within 6 hours for at least 5 days),
access conditions were changed to a discrete-trials sche-
dule. During the discrete-trial schedule, rats were given
access to cocaine for 10-min discrete trials that were
initiated at 15-min intervals. An infusion (1.5 mg/kg/inj)
of cocaine was given following a response on the lever,
which resulted in illumination of a stimulus light for 20
sec. The lever was retracted and the trial terminated if
an injection was collected or if 10 minutes had elapsed.
Rats received four discrete trials per hour (i.e., DT4),
24 hours per day, for 10 days. Following 10 days of
self-administration, animals were placed in standard
polycarbonate cages for 1, 10 or 100 days of enforced
abstinence. All research was approved by the Wake
Forest University School of Medicine and Penn State
College of Medicine Animal Care and Use Committees
and conducted according to the Guide for the Care and
Use of Laboratory Animals, as promulgated by the
National Institutes of Health.
Dissection
Following 1, 10, or 100 days of deprivation, rats were
sacrificed and the brains were rapidly removed and
cooled in ice-chilled saline. Brains were then placed in
an ice-chilled ASI brain slicer (ASI Instruments, Warren
MI). The medial prefrontal cortex (mPFC) and nucleus
accumbens (NAc) were collected as described previously
[12]. Briefly, the section from Bregma +4.4 to 2.4 mm
[81] was cut along the forceps minor and the cortex
medial of this cut was collected. This is considered the
medial prefrontal cortex, and includes the cingulate
area, prelimbic cortex, and medial orbital cortex. The
s e c t i o nf r o m+2 . 2t o0 . 2m mw a sc u t0 . 5m mo ne a c h
side of the midline, on a line connecting the tip of the
external capsule and the previous cut, on a line connect-
ing the tip of the external capsule and lateral ventricle,
and between the ventricle. This dissection includes both
the core and the shell of the NAc. See Additional File 3:
Figure S1, for schematics of the dissections.
RNA isolation
Following dissection, tissue samples were stored at -80°C
until RNA was isolated. RNA isolation was conducted as
described previously [74,82]. Total RNA from cocaine
naïve rats and rats following 1, 10, and 100 days of
enforced abstinence (following 10 days of DT4 cocaine
self-administration as described above) was isolated
using Tri-Reagent (Molecular Research Center Inc.,
Freeman et al. BMC Neuroscience 2010, 11:29
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then assessed using the Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, CA) following further RNA purification
using an RNeasy Mini Kit for RNA clean-up (Qiagen
Sciences, Maryland).
Microarray analysis
Microarray analysis was performed in the Penn State
College of Medicine Functional Genomics Core Facility
according to standard procedures. For the mPFC arrays,
naïve, 1-day, and 100-day abstinent samples were used
(N = 6). For the NAc arrays, naïve, 1-day and 10-day
abstinent samples were used (N = 5; reduced sample
number due to removal of samples that did not pass
array quality control). Microarrays for the NAc were
performed after those for the mPFC, and for the NAc,
the 10-day timepoint was used instead of the 100-day
timepoint in order to detect important changes that
may not last to 100 days of abstinence. The persistence
of these changes to 100-days could then be tested with
qPCR.
Microarray analysis was performed using the Code-
Link Rat Whole Genome Bioarray system (GE Health-
care). Following the manufacturer’s protocol, first strand
synthesis was performed with 2 μg of RNA as starting
material and was followed by second strand synthesis
and purification using Qiaquick spin columns (Qiagen,
Valencia, CA). T7 reaction buffer, T7 NTPs, 10 mM
biotin-11-UTP, and T7 polymerase were then added to
the dsDNA for the IVT reaction and incubated at 37°C
for 14 hours. The resulting Biotin-labeled cRNA was
then purified using RNEasy columns (Qiagen), quanti-
tated, and volume-adjusted for a total of 10 μL. The
cRNA was then fragmented and denatured before hybri-
dization for 18 hours at 37°C. Slides were washed and
then incubated at room temperature with Alexa Fluor
647 labeled streptavidin for 30 minutes followed by
washing.
M i c r oa r r a y sw e r es c a n n e do na nA x o n4 0 0 0Bs c a n -
ner with GenePix4 v4.0 software at a 5 μm resolution at
635 nm with laser power at 100%, PMT voltage at 600
V, focus position 0 μm, and lines to average = 1. Images
were then imported into CodeLink Expression Analysis
Software v4.1 (GE Healthcare) and initial quality control
(positive and negative controls), exclusion of manufac-
turing defects (MSR spots), background subtraction, and
intra-array normalization was performed.
Data analysis
Following image analysis on CodeLink Expression Ana-
lysis Software, microarray data were imported into
GeneSpring GX 7.3 (Agilent Technologies) and signal
values less than 0.01 were transformed to an intensity of
0.01. Normalization was performed per chip to the 50
th
percentile, and per gene to the median. Values were
then normalized on a per gene basis to the naïve group
for each of the two time points (1 and 10, or 1 and 100
days of abstinence). Potential differential expression was
determined with a one-way ANOVA (variances not
assumed to be equal), p < 0.05 and filtered for 1.4-fold
or greater differences in expression in accordance with
standards for microarray analysis [84]. The use of a
combination of statistical and fold-change cutoffs as
opposed to traditional multiple testing corrections (e.g.,
Bonferroni post-hoc testing) produce gene lists with the
lowest rate of type I and type II errors [85]. A fold-
change cutoff of 1.4 fold was chosen, as this magnitude
change is at the lower range of changes historically con-
firmed by qPCR in this laboratory. Lastly, probe
sequences on the array were searched against current
rat genome sequences to eliminate any probes for
sequences removed from the NCBI database.
Quantitative PCR (qPCR) analysis of gene expression
cDNA synthesis was performed on total RNA from naïve,
1, 10, and 100-day abstinent animals using Superscript III
Reverse Transcriptase (Invitrogen, Carlsbad, CA). 1 μg
RNA, 500 ng Oligo (dT), and 10 mM each dNTP, were
incubated for 5 minutes at 65°C and then chilled on ice
for 2 minutes. 5× First Strand Buffer (250 mM Tris-HCl
(pH8.3), 375 mM KCl, and 15 mM MgCl2), 5 mM DTT
(final concentration), 40 U RNaseOut, and 200 U Super-
script III RT were then added. The 20 μl reaction was
incubated for 60 minutes at 50°C followed by a final
incubation at 70°C for 15 minutes for termination. The
resulting cDNA product was quantified and 50 ng of pro-
duct was used in each subsequent qPCR reaction.
Quantitative PCR was carried out on a real-time
detection instrument (ABI 7900HT Sequence Detection
System) in 384-well optical plates using TaqMan Uni-
versal PCR Master Mix and Assay on Demand primers
and probes (Applied Biosystems, Foster City, CA) as
described previously [86,87]. This examination used a
larger set of animals than the microarray analysis (Table
1). Primer/probe sets used are listed in Additional File
2: Table S2. SDS 2.2.2 software and the 2
-ΔΔCt analysis
method [88]. were used to quantitate relative amounts
of product using b-actin as an endogenous control. Sig-
nificance from qPCR analysis was determined with Sig-
maStat 3.5 (SYSTAT Software, Inc.) based on one-way
analysis of variance (ANOVA) (p < 0.05) with a post hoc
Student Newman-Keuls test (p < 0.05).
Ontological, pathway, and network analysis
Ontological analysis used Gene Ontology (GO) cate-
gories and differentially expressed processes or func-
tional categories were determined statistically, as
previously described [87] using GeneSpring GX
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i nac a t e g o r yp r e s e n to nt h ea r r a ya n dt h en u m b e ro f
expression changes that would be part of that category
by random chance given the number of differentially
expressed genes. Results from these analyses were used
to compile a list of genes to examine by qPCR. Ingenu-
ity Pathway Analysis (Ingenuity Systems, Redwood City
CA) was used for network and pathways analysis of the
qPCR confirmed gene expression results.
Additional file 1: Microarray expression data. A full listing of
differentially expressed genes identified by microarray analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-
29-S1.DOC]
Additional file 2: Gene expression assay numbers. Gene symbols, full
names and gene expression assay numbers.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-
29-S2.XLS]
Additional file 3: Dissection schematics. Dissection diagrams.
Schematics of the mPFC and NAc dissections are provided using
modifications of figures from Paxinos and Watson. Numbered red lines
are specific dissection cuts using visible landmarks as described in the
methods. The shaded area represents the tissue collected for molecular
analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-
29-S3.PDF]
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